Figure S8. c-Abl and Arg expression in primary melanomas and breast cancers. (a-c). Data from Oncomine™ (Compendia Bioscience, Ann Arbor, MI) was downloaded and statistically reanalyzed using two sample t-tests. **(a)** Talantov study. c-Abl (Abl1) and Arg (Abl2) expression is increased in primary melanomas relative to normal skin. Abl, p=1.7E-4, Fold change=3.17; Arg, p=0.03, fold=1.7. **(b,c)** Riker study. **(b)** Arg (Abl2) is overexpressed in melanomas vs. normal skin. Average of three independent probe sets. Arg p=6.5E-5, fold change=2. **(c)** Arg expression is greater in metastases than in primary melanomas. Average of 3 probe sets. p=0.01, fold=1.56. **(d,e)** BR10010a TMAs serial sections were stained with pCrk/CrkL antibody. Graphs are Mean±SEM of scores (intensity * proportion of positively staining tumor cells). **(f)** 435s cells were transfected with scrambled or NM23-H1 siRNAs, and stained with NM23-H1 antibody (D98, used for immunohistochemistry), followed by fluorescent-conjugated secondary antibodies, and counterstained with DAPI. **(g)** Immunohistochemical staining using pCrk/CrkL, NM23-H1 or rabbit IgG antibodies in a breast cancer TMA.